Perceptive Advisors Llc - Dec 27, 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director, 10%+ Owner
Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol
ATHA
Transactions as of
Dec 27, 2023
Transactions value $
$1,462,895
Form type
4
Date filed
12/29/2023, 05:24 PM
Previous filing
Dec 22, 2023
Next filing
Jan 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Purchase $73.3K +32.1K +0.67% $2.28 4.83M Dec 27, 2023 See Footnote F1, F4
transaction ATHA Common Stock Purchase $999K +410K +8.48% $2.44 5.24M Dec 28, 2023 See Footnote F2, F4
transaction ATHA Common Stock Purchase $390K +164K +3.13% $2.38 5.4M Dec 29, 2023 See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.195 to $2.31, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.265 to $2.50, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.295 to $2.44, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
F4 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor and a director of the Issuer. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.